Clinical Trial Update: Phase II Trial of ZD1839 (Iressa) in Patients With Nonresectable Adrenocortical Carcinoma (ACC) [Phase 2]

View source ↗

Summary

A Phase II study evaluating ZD1839 (Iressa) in patients with nonresectable adrenocortical carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adrenocortical Carcinoma

Drugs mentioned

• Iressa (gefitinib)

Snippet

Sponsor: Dartmouth-Hitchcock Medical Center | Conditions: Nonresectable Adrenocortical Carcinoma | Phase 2 | Status: COMPLETED